Effects of Empagliflozin on Calcium, Phosphate, and Magnesium Levels in Adults with Autosomal Dominant Polycystic Kidney Disease

What this Trial Is About

Researchers are investigating how the SGLT2 inhibitor Empagliflozin affects the handling of important minerals like calcium, phosphate, and magnesium in patients with autosomal dominant polycystic kidney disease ADPKD. This phase 2, randomized, single-blind, placebo-controlled crossover study aims to improve understanding of kidney function related to these minerals in this patient group. Participants will be randomly assigned to receive either Empagliflozin 10mg or a placebo for two weeks. This is followed by a two-week wash-out period without treatment. After the wash-out, participants will switch to the other treatment for another two weeks. Throughout the study, urine and blood samples will be collected to monitor the effects. During the study, participants will provide 24-hour urine samples and attend clinical visits for vital signs and blood tests at multiple time points. Phone consultations will be conducted to assess safety. The main measure is how the kidneys handle calcium, phosphate, and magnesium after two weeks of treatment, with additional measurements including urine output, safety, and tolerability. The total study duration spans about six weeks per participant.

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease